FDA approves Wezlana for multiple inflammatory diseases
Nov 02, 2023
Approval of the biosimilar allows for interchangeable use with Stelara in both adult and pediatric patients
Skyrizi approved for psoriatic arthritis
Jan 26, 2022
The approval was based on two Phase 3 trials showing that more than 50% of patients receiving Skyrizi achieved an ACR20 response at 24 weeks.
Road traffic, railway noise linked to increased dementia risk
Sep 10, 2021
The general pattern showed higher hazard ratios with higher noise exposure, with levelling off or a decline at higher noise levels.
Medicare will cover new class of Alzheimer’s drugs if fully approved by FDA, with limits
Jun 02, 2023
Drug makers also will have to gather and keep data in a registry showing how the drugs are working in the real world.
European Union passes U.S. in COVID-19 vaccination rates
Aug 09, 2021
Rates of people in the 27-member EU with at least one dose have climbed from less than 4% in mid-February to 60%, whereas rates in the United States rose from nearly 12% to less than 58%.
FDA approves second OTC naloxone spray for suspected opioid overdose
Aug 03, 2023
The American Medical Association applauded the approval to improve access to nonprescription naloxone as a way to curb the opioid epidemic.
FDA approves new antibiotic for uncomplicated urinary tract tnfections
Apr 30, 2024
Approval of Pivya is for female adults with UTIs caused by susceptible isolates of E. coli, P. mirabilis,and S. saprophyticus.
FDA approves new two-drug combo medicine for asthma
Jan 12, 2023
The medication is the first approved in the United States to contain an inhaled corticosteroid as a reliever rather than as a controller of asthma symptoms.
No fewer deaths seen with restricted IV fluid for septic shock
Jun 17, 2022
The rates of death at 90 days, serious adverse events, did not differ for patients with septic shock receiving restricted versus standard IV fluid therapy in the ICU.
Most COVID-19-related EUAs not supported by high-quality evidence
Dec 30, 2021
For drugs and vaccines, the emergency use authorizations were mostly supported by randomized clinical trials.